Original Articles

Study of Validity of PC-3 Derived Xenograft Tumor Model in Athymic Nude Mice for Targeting Therapy of Androgen Receptors in Preclinical Studies of Prostate Cancer

Abstract

Background: Androgen receptors (AR) play an important role in proliferation of cancerous prostatic cells and prevention of apoptotic signaling. Current drugs cannot inhibit the activity of these receptors very well. Establishment of appropriate animal models is essential for discovery of new drugs of target therapy in hormone dependent prostate cancer.Materials and Methods: Standard prostatic cancer cell line (PC-3) was injected heterotopically into 9 nude mice. After tumor formation they were excised and sent for histopathologic and AR expression studies by immunohistochemistry.Results: Histological characteristics of prostate cancer were confirmed. Androgen receptors had been expressed in 65 ± 25% of the xenograft tumor cells.Conclusions: This xenograft model is suitable for pharmacological and molecular studies of androgen dependent prostate cancer.

- Zelefsky M, Eastham J, Sartor O, Kantoff P. Cancer of the Prostate. Cancer Principles & Practice of Oncology. Editors: DeVita V, Lawrence T. Rosenberg S. 8th Edition. 2008 Lippincott Williams & Wilkins. Chap 40: sec 6. P:1395

- Crawford E. Epidemiology of Prostate Cancer. Journal.urology.2003. No:10. P:013

- Saez J, Otero M, Dominguez M, Peñuelas A, et al. Diagnostic Methods in the Detection of Prostate Cancer: Prospective Observational Study. Current Medical Imaging Reviews, 2007, 3. P: 27-35

- Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007 Dec;28(7):778-808

- Gardiner R, Sweeney C, Tilley W. Testosterone Therapy in Castrate- Resistant Prostate Cancer: A Possible New Approach. journal European urology.2009. Vol:03, P: 73

- Noori Daloii M R. Ebrahimzadeh Vesal E. Molecular genetic, diagnosis, prevention and gene therapy in prostatic cancer: review article. Tehran University medical Journal. Vol 67, No 1, April 2009. P:1-14

- Ousati Ashtiani Z, Ayati M, Sabah Golian B, et al. Association of CAG repeats of androgen receptor gene (Isoform I) with prostate cancer and benign prostatic hyperplasia. Tehran University Medical Journal; 2008. Vol. 65, Supplement 3, 20-25

- Nicol´as D´ıaz-Chico B, Germ´an Rodr´ıguez F, Gonz´alez A. et al. Androgens and androgen receptors in breast cancer. Journal of Steroid Biochemistry & Molecular Biology, 2007. No 105. P:1–15

- Brooke GN, Bevan CN. The Role of Androgen Receptor Mutations in Prostate Cancer Progression. Current Genomics, 2009,No: 9, P: 18-25

- Miyamoto H, Messing E, Chang C. AndrogenDeprivationTherapy for ProstateCancer: Current Status and Future Prospects. The Journal of Prostate. 2004. No:1 P: 1-22

- Tomayko MM, Reynolds CP. Determination of Subcutaneous Tumor Size in Athymic (Nude) Mice. Cancer Chemother. Pharmacol. 1989. 24: I48-I54.

- Kantarjian H, Wolff R, Koller Ch, et al. Anderson Manual of Medical Oncology. McGraw-Hill’s.2005. Part IX. Chap:26.

- Francesca M, Paola E, Giuliano M, et al. Metastatic Prostate Cancer After Orchiectomy, Radiotherapy and Testosterone Replacement in a Patient With Bilateral Seminoma. Journal of Andrology. 2007. Vol 28, No 1,P: 10-13

- De paula A, Piccelli H, et al. Economical Impact of Orchiectomy for Advanced Prostate Cancer. Int Braz J Urol. 2003;No: 29. P:27-32

- Fauci A, Kasper D, Longo D. Harrison’s Principles of Internal Medicine. 17th Edition. McGraw-Hill’s.2008. Part 6, sec 1. Chap 96.

- Raina R, Pahalajani G, Agarwal A, e tal. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1–2) : a retrospective study. Asian J Androl 2007; 9 (2): 253–258

- Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of Tamoxifen and Anastrozole in the Prevention of Gynecomastia and Breast Pain Induced by Bicalutamide Monotherapy of Prostate Cancer. Journal of Clinical Oncology. 2005, Vol 23, Number4, February.P:808-815

- Kaighn ME, Narayan KS, Ohnuki Y, et al. Establishment and characterization of a human prostatic 0

- Pulukuri SM, Gondi CS, Lakka SS, et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem. 2005 Oct 28. Vol:28.No:43. P:29-40.

- Lung Lin S, Chang D, Chiang A, et al. Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogen Oxford Journal. Vol 29. P:282-290

- Kollara A, Diamandis E, Brown T. Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. Journal of Steroid Biochemistry & Molecular Biology.2003.No: 84 . P:493–502

- Bonaccrsi L, Carloni V, Muratori M, et al. Androgen Receptor Expression in Prostate Carcinoma Cells Suppresses a6b4 Integrin-Mediated Invasive Phenotype. Journal Endocrinology.2000 Vol. 141, No. 9 P: 3172-3182

Files
IssueVol 3 No 2 (2011) QRcode
SectionOriginal Articles
Keywords
Androgen receptor prostate cancer xenograft model Athymic nude mice
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Muhammadnejad S, Muhammadnejad A, Mazaheri Z, Tirgari F, Oghabian M-A, Kazem haghighi M, Amanpour S. Study of Validity of PC-3 Derived Xenograft Tumor Model in Athymic Nude Mice for Targeting Therapy of Androgen Receptors in Preclinical Studies of Prostate Cancer. Basic Clin Cancer Res. 2016;3(2):42-45.